Experience with sonidegib in patients with advanced basal cell carcinoma: case reports

Sonidegib is a Hedgehog signalling pathway inhibitor approved for use in patients with advanced basal cell carcinoma (BCC) not eligible for surgery or radiotherapy. This report describes clinical experience with sonidegib in two patients with locally advanced BCC (one with a tumour adjacent to the r...

Descripción completa

Detalles Bibliográficos
Autores principales: Puig, Susana, Serra-Guillén, Carlos, Pérez-Pastor, Gemma, Martínez-Domenech, Álvaro, Fernández-de-Misa Cabrera, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132536/
https://www.ncbi.nlm.nih.gov/pubmed/35677182
http://dx.doi.org/10.7573/dic.2022-3-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132536/
https://www.ncbi.nlm.nih.gov/pubmed/35677182
http://dx.doi.org/10.7573/dic.2022-3-8

Ejemplares similares